- Home
- CWAN vs HALO Comparison
CWAN vs HALO Comparison
Compare CWAN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWAN
- HALO
- Stock Information
- Founded
- CWAN 2004
- HALO 1998
- Country
- CWAN United States
- HALO United States
- Employees
- CWAN N/A
- HALO N/A
- Industry
- CWAN Computer Software: Prepackaged Software
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CWAN Technology
- HALO Health Care
- Exchange
- CWAN Nasdaq
- HALO Nasdaq
- Market Cap
- CWAN 7.3B
- HALO 7.4B
- IPO Year
- CWAN 2021
- HALO N/A
- Fundamental
- Price
- CWAN $24.22
- HALO $48.99
- Analyst Decision
- CWAN Buy
- HALO Buy
- Analyst Count
- CWAN 9
- HALO 9
- Target Price
- CWAN $32.44
- HALO $63.78
- AVG Volume (30 Days)
- CWAN 3.5M
- HALO 2.6M
- Earning Date
- CWAN 04-30-2025
- HALO 05-06-2025
- Dividend Yield
- CWAN N/A
- HALO N/A
- EPS Growth
- CWAN N/A
- HALO 55.40
- EPS
- CWAN 1.71
- HALO 3.76
- Revenue
- CWAN $475,948,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- CWAN $21.92
- HALO $24.79
- Revenue Next Year
- CWAN $18.92
- HALO $22.65
- P/E Ratio
- CWAN $14.23
- HALO $13.36
- Revenue Growth
- CWAN 23.21
- HALO 25.64
- 52 Week Low
- CWAN $17.42
- HALO $41.28
- 52 Week High
- CWAN $35.71
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- CWAN 55.48
- HALO 33.26
- Support Level
- CWAN $23.91
- HALO $48.10
- Resistance Level
- CWAN $24.63
- HALO $69.94
- Average True Range (ATR)
- CWAN 0.68
- HALO 3.31
- MACD
- CWAN 0.35
- HALO -1.04
- Stochastic Oscillator
- CWAN 84.93
- HALO 3.96
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics Holdings Inc provides a SaaS solution for automated investment data aggregation, reconciliation, accounting and reporting services to insurers, investment managers, corporations, institutional investors and government entities. It earns revenue from providing access to its SaaS platform to customers, services that support the implementation on the SaaS platform, selling perpetual and term-based software licenses and providing maintenance and support and professional services under contracts with customers. The majority of the revenue is earned in the United States.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.